Andere Sprachen Lunit Inc.

Aktien

A328130

KR7328130000

A328130

Schlusskurs Korea S.E. Andere Börsenplätze 00:00:00 24.06.2024			% 5 Tage	% 1. Jan.
45.000 ^KRW	-2,81 %		-9,27 %	-45,05 %

24.05.	Lunit stellt 7 Studien auf der Asco 2024 vor, darunter Ai-Innovationen zur Her2-Quantifizierung und multimodale Vorhersagemodelle für das Ansprechen auf Immuntherapien	CI
13.05.	Lunit Inc. (KOSDAQ:A328130) hat die Übernahme von Volpara Health Technologies Limited (ASX:VHT) von Harbour Asset Management Limited und anderen abgeschlossen.	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Lunit Inc. announced that it has received KRW 171.5 billion in funding from a group of investors	31.05.
Lunit to Showcase 7 Studies at Asco 2024, Including Ai Innovations in Her2 Quantification, and Multimodal Predictive Models for Immunotherapy Response	24.05.
Lunit Acquires New Zealand's Volpara Health Technologies	23.05.
Lunit Inc. completed the acquisition of Volpara Health Technologies Limited from Harbour Asset Management Limited and others.	13.05.
Volpara to Delist After Court Approves Acquisition by Lunit	03.05.
Lunit Wins Shareholder Approval for Volpara Health Takeover	16.04.
Volpara Health Technologies Secures Approval for Lunit’s Proposed Takeover	12.04.
Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals	08.04.
Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients	27.03.
Lunit Announces Publication of New Study Featuring Lunit SCOPE IO	26.03.
Lunit Announces Two Commercial Deals Signal its Expansion in Europe	18.03.
Lunit SCOPE AI Enhances Pathologist Concordance and Accuracy in HER2, ER, and PR Assessment, New Study in Breast Cancer Research	15.03.
Lunit Inc. Receives Two Supply Contracts That Mark Its Strategic Expansion into the East and Southeast Asian Region	11.03.
Lunit Presents Seven Study Results at ECR 2024, Showcasing AI's Robust Performance in Diverse Clinical Settings	29.02.
New Study Demonstrates Predictive Value of Lunit SCOPE IO to Predict Outcomes of Immune Checkpoint Inhibitor Therapy across Diverse Tumors, published in the JITC	19.02.
Lunit INSIGHT CXR Excels in Long Nodule Detection, Exceptional Performance in Head-to-Head Study published in Radiology	18.01.
Lunit Announces Three-Year Supply Contract with Samsung Electronics	16.01.
GC Cell Signs Agreement with Lunit for AI-Powered Cancer Treatment	26.12.
Lunit to Acquire Volpara, Scheme Implementation Agreement Signed	15.12.
Lunit to Take Over Volpara Health; Lunit Shares Decline 4%	15.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Lunit Inc.

Aktien

A328130

KR7328130000

A328130

Andere Sprachen

Filter